Physician profile
Scott E Ruder
NPI 1790733939
$5,826.87
in general payments reported to CMS, 2019-2025
32 companies · $851 in 2025
The $851 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $623 · 2021: $996 · 2022: $719 · 2023: $678 · 2024: $715 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $740.27 | 2019-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $723.87 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $498.44 | 2019-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $489.30 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $408.73 | 2019-2025 | Trintellix |
| Lundbeck LLC | $346.30 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $341.42 | 2019-2021 | |
| Alkermes, INC. | $249.04 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $221.06 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $195.89 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $170.45 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.55 | 2020-2024 | Caplyta |
| Noven Therapeutics, LLC | $148.46 | 2021-2025 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $143.85 | 2022-2023 | Qelbree |
| Jazz Pharmaceuticals INC. | $133.32 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $119.82 | 2019-2025 | Aplenzin |
| Neos Therapeutics, Lp | $85.35 | 2020-2022 | |
| Livanova USA, INC. | $77.04 | 2022-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Adlon Therapeutics L.P. | $74.70 | 2020-2021 | |
| Eisai INC. | $72.85 | 2020-2021 | |
| Corium, LLC | $72.32 | 2022-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $64.77 | 2025 | Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $44.17 | 2019-2020 | |
| Tris Pharma INC | $43.73 | 2023 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $35.25 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $32.23 | 2022 | |
| Collegium Pharmaceutical, INC. | $30.87 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $29.77 | 2025 | |
| Shire North American Group INC | $19.51 | 2019 | |
| Almatica Pharma LLC | $19.39 | 2021 | |
| Noven Pharmaceuticals, INC. | $17.04 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ruder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.